A comparison of serum oestrogen levels after percutaneous and oral administration of oestradiol-17 beta. 1981

S Lyrenäs, and K Carlström, and T Bäckström, and B von Schoultz

Equivalent doses of oestradiol-17 beta were given orally and percutaneously to eight post-menopausal women and three men. The resultant serum levels of unconjugated immunoreactive oestrogens and total oestrone were followed during 48 hours after hormone administration. A single percutaneous dose of 4 mg oestradiol-17 beta resulted in increased serum levels of oestradiol-17 beta in all individuals. Compared to oral administration the increase in serum oestrogen levels was quite slow and they were maintained for 48 hours. In contrast to the rapid and very marked increase in serum total oestrone following oral administration of oestradiol-17 beta, only a moderate increase was obtained after percutaneous administration and there was a tendency to a biphasic pattern. Topical administration of oestradiol-17 beta might have physiological advantages as the steroid will reach the peripheral circulation without passing the entero-hepatic circulation.

UI MeSH Term Description Entries
D007271 Injections, Intradermal The forcing into the skin of liquid medication, nutrient, or other fluid through a hollow needle, piercing the top skin layer. Intradermal Injections,Injection, Intradermal,Intradermal Injection
D008297 Male Males
D008593 Menopause The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age. Change of Life, Female
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004958 Estradiol The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. 17 beta-Estradiol,Estradiol-17 beta,Oestradiol,17 beta-Oestradiol,Aerodiol,Delestrogen,Estrace,Estraderm TTS,Estradiol Anhydrous,Estradiol Hemihydrate,Estradiol Hemihydrate, (17 alpha)-Isomer,Estradiol Monohydrate,Estradiol Valerate,Estradiol Valeriante,Estradiol, (+-)-Isomer,Estradiol, (-)-Isomer,Estradiol, (16 alpha,17 alpha)-Isomer,Estradiol, (16 alpha,17 beta)-Isomer,Estradiol, (17-alpha)-Isomer,Estradiol, (8 alpha,17 beta)-(+-)-Isomer,Estradiol, (8 alpha,17 beta)-Isomer,Estradiol, (9 beta,17 alpha)-Isomer,Estradiol, (9 beta,17 beta)-Isomer,Estradiol, Monosodium Salt,Estradiol, Sodium Salt,Estradiol-17 alpha,Estradiol-17beta,Ovocyclin,Progynon-Depot,Progynova,Vivelle,17 beta Estradiol,17 beta Oestradiol,Estradiol 17 alpha,Estradiol 17 beta,Estradiol 17beta,Progynon Depot
D004967 Estrogens Compounds that interact with ESTROGEN RECEPTORS in target tissues to bring about the effects similar to those of ESTRADIOL. Estrogens stimulate the female reproductive organs, and the development of secondary female SEX CHARACTERISTICS. Estrogenic chemicals include natural, synthetic, steroidal, or non-steroidal compounds. Estrogen,Estrogen Effect,Estrogen Effects,Estrogen Receptor Agonists,Estrogenic Agents,Estrogenic Compounds,Estrogenic Effect,Estrogenic Effects,Agents, Estrogenic,Agonists, Estrogen Receptor,Compounds, Estrogenic,Effects, Estrogen,Effects, Estrogenic,Receptor Agonists, Estrogen
D004970 Estrone An aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone, a major mammalian estrogen. It is converted from ANDROSTENEDIONE directly, or from TESTOSTERONE via ESTRADIOL. In humans, it is produced primarily by the cyclic ovaries, PLACENTA, and the ADIPOSE TISSUE of men and postmenopausal women. Folliculin (Hormone),Estrone, (+-)-Isomer,Estrone, (8 alpha)-Isomer,Estrone, (9 beta)-Isomer,Estrovarin,Kestrone,Unigen,Wehgen
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

S Lyrenäs, and K Carlström, and T Bäckström, and B von Schoultz
October 1984, British journal of obstetrics and gynaecology,
S Lyrenäs, and K Carlström, and T Bäckström, and B von Schoultz
July 1961, Acta endocrinologica,
S Lyrenäs, and K Carlström, and T Bäckström, and B von Schoultz
September 1979, British journal of obstetrics and gynaecology,
S Lyrenäs, and K Carlström, and T Bäckström, and B von Schoultz
December 1982, Acta endocrinologica,
S Lyrenäs, and K Carlström, and T Bäckström, and B von Schoultz
January 1973, Comptes rendus des seances de la Societe de biologie et de ses filiales,
S Lyrenäs, and K Carlström, and T Bäckström, and B von Schoultz
February 1986, Journal of steroid biochemistry,
S Lyrenäs, and K Carlström, and T Bäckström, and B von Schoultz
June 1974, British journal of cancer,
S Lyrenäs, and K Carlström, and T Bäckström, and B von Schoultz
December 1989, Maturitas,
S Lyrenäs, and K Carlström, and T Bäckström, and B von Schoultz
December 1979, IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans,
Copied contents to your clipboard!